Development and production facilities for medical devices are being implemented in VitaCity for the biomaterials company Bonalive Biomaterials Oy. The VitaCity building at Biolinja 2 is being renovated…
Development and production facilities are being renovated in the VitaCity building at Biolinja 2 for the Turku-based company Bonalive Biomaterials Oy. Bonalive Biomaterials is a health technology company founded in 2009 that develops and manufactures bioactive glass implanted into the human body, used to replace bone and treat infections.
Bonalive Biomaterials is leasing approximately 2,400 square meters of VitaCity under a long-term lease agreement. The two-story building, completed in 2002, was originally built as a research and development facility, and is now being converted to meet the needs of Bonalive Biomaterials. The largest change concerns the cleanrooms; in addition, the office premises are being renovated into a multi-space environment. The changes will not affect the building's facade. The renovation is being carried out by Rakennustoimisto Lundén Oy and Calto Oy. Demolition work is already underway, and the project will be completed at the turn of the year.
“With our new premises, we will be able to meet the growing demand in the global infection market.”
Bonalive Biomaterials will move into the new premises at the beginning of 2025. The company, which employs 40 people, currently operates in, among others, ICT-City and IndustryCity, and has subsidiaries in Germany, Italy, and the United States.
“With the new premises, it is possible to increase our production volume significantly, and we will be able to respond even better to the growing demand in the global infection market. Bringing the manufacturing, testing, innovation, and quality assurance of bone substitute and infection solution products under one roof will also streamline our operations. Our goal is to promote the transition to sustainable infection solutions, and in the future, we see our products enabling a world where infections are treated without antibiotics,” says Heidi Rantala, CEO of Bonalive Biomaterials.
At Teknologiakiinteistöt, the project is seen as a significant continuation of the development of the Science Park, helping to increase the number of innovation players and jobs in the area.
“We are happy to be involved in enabling premises for an innovative player that creates products for the future,” says Mikko Lehtinen, CEO of Teknologiakiinteistöt.
KOy VitaCity is owned by Turun Teknologiakiinteistöt (50%), Ella Kodit Oy, and Waiwela Oy.
More information:
Mikko Lehtinen
CEO, Turun Teknologiakiinteistöt Oy
Tel. 0400 960 626
Heidi Rantala
CEO, Bonalive Biomaterials Oy
Tel. 045 132 0207
Bonalive Biomaterials Oy is a biomaterials company offering intelligent infection solutions, manufacturing bioactive glass that promotes the growth and attachment of human bone tissue. Bonalive Biomaterials operates in Turku and has subsidiaries in Germany, Italy, and the United States, as well as distribution activities in over 40 other countries. The company's mission is to change the future of healthcare through technologies based on strong clinical evidence.